ValiRx Plc (LON:VAL) has appointed a specialist investor relations firm to build its recognition among academic, clinical, and business leaders in the US.
Burns McClellan has already carried out an institutional investor introductory project for ValiRx.
Satu Vainikka, ValiRx’s chief executive, said its relationship with Burns McClellan was developing strongly and the company would benefit from enhanced engagement with US investors and other key partners in the US biotech sector.
ValiRx has one drug, VAL201 targeting prostate cancer, going through phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401 that focuses on locally advanced or metastatic non-small cell lung cancer.